These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32158335)

  • 1. Characteristics of Advanced Colorectal Cancer Detected by Fecal Immunochemical Test Screening in Participants with a Negative Result the Previous Year.
    Hasegawa R; Yashima K; Ikebuchi Y; Sasaki S; Yoshida A; Kawaguchi K; Isomoto H
    Yonago Acta Med; 2020 Feb; 63(1):63-69. PubMed ID: 32158335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of the immunochemical fecal occult blood test for colorectal cancer screening in Brazil.
    Teixeira CR; Bonotto ML; Lima JP; Figueiredo LF; Conrado L; Frasca C
    Ann Gastroenterol; 2017; 30(4):442-445. PubMed ID: 28655982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of the Fecal Immunochemical Test in Patients With a Family History of Colorectal Cancer.
    Moosavi S; Gentile L; Gondara L; Mcgahan C; Enns RA; Telford J
    J Can Assoc Gastroenterol; 2020 Dec; 3(6):288-292. PubMed ID: 33241182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Features of Fecal Immunochemical Test-Negative Colorectal Lesions based on Colorectal Cancer Screening among Asymptomatic Participants in Their 50s.
    Suto S; Matsuzaka M; Sawaya M; Sakuraba H; Mikami T; Matsuda T; Fujii T; Saito Y; Hotta K; Ikematsu H; Hanabata N; Saito H; Yoshida S; Fukuda S
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2325-2332. PubMed ID: 35901338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
    van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
    United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proportions and characteristics of interval cancer in annual fecal immunochemical test screening and postcolonoscopy colorectal cancer: Results from a Japanese multicenter prospective study using questionnaires, the C-DETECT study.
    Sekiguchi M; Kishida Y; Ikematsu H; Konno M; Mizuguchi Y; Hotta K; Imai K; Ito S; Takada K; Shiomi A; Yasui H; Tsukamoto S; Hirano H; Kobayashi N; Saito Y; Inaba A; Shinmura K; Konishi J; Ozawa H; Fujita S; Murakami Y; Matsuda T
    Dig Endosc; 2024 Mar; ():. PubMed ID: 38433322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
    Ribbing Wilén H; Blom J
    J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimate of Increase in Colorectal Cancer Diagnoses with Expansion of Fecal Immunochemical Testing in an Urban Safety-Net Population.
    Connolly JJ; Ahmed HS; Chung EC; Cabral HJ; Nagar A; Tami A; Schroy PC; Mohanty A
    Dig Dis Sci; 2024 Feb; 69(2):360-369. PubMed ID: 38041763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study.
    Breekveldt ECH; Lansdorp-Vogelaar I; Toes-Zoutendijk E; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Nagtegaal ID; Krul MF; Kok NFM; Kuhlmann KFD; Vink GR; van Leerdam ME; Elferink MAG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):60-68. PubMed ID: 34822762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.
    Kooyker A; de Jonge L; Toes-Zoutendijk E; Spaander M; van Vuuren H; Kuipers E; van Kemenade F; Ramakers C; Dekker E; Nagtegaal I; van Leerdam M; Lansdorp-Vogelaar I
    Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3424-3432.e2. PubMed ID: 37619823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings.
    Elsafi SH; Alqahtani NI; Zakary NY; Al Zahrani EM
    Clin Exp Gastroenterol; 2015; 8():279-84. PubMed ID: 26392783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study.
    Kubisch CH; Crispin A; Mansmann U; Göke B; Kolligs FT
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1612-1618.e3. PubMed ID: 27085763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.